Good morning. Here are the top deals headlines I found for my Monday morning update across medical devices and biotechnology. News comes from cancer care, immunology, drug discovery AI and more. Let me know if I have missed anything and congratulations to everyone involved.
– UK DNA technology in line for £650m investment in bid to fight serious illness. The investment in genomics is expected to support the Government’s 10-year plan for the NHS.
– Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures.
– A startup banks $66M to pursue ‘inclusive precision medicine’. Actio Biosciences’ Series B round will be used to support research initially focused on rare diseases, but it sees having broad potential, too.
– Belgian early-stage investor biotope raises €5 million to support up to 30 international BioTech startups
– HealthTech scale-up Perci Health, a comprehensive virtual cancer clinic out of the UK, has successfully closed a €4 million funding round,
– British life sciences startup Kiin Bio has secured an oversubscribed €1.9 million pre-Seed investment round to launch their Virtual Scientist Platform for drug discovery, KiinOS
– A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in major depressive disorder. Draig Therapeutics has emerged from a partnership between Cardiff University’s Medicines Discovery Institute and SV Health Investors to tackle unmet need in neuropsychiatry.
– Eli Lilly has bought gene editing partner Verve Therapeutics for $1.3 billion, bringing in-house a pipeline of cardiovascular programs the Big Pharma had already secured a stake in.
– Harvard University’s Gökhan Hotamışlıgil, M.D., Ph.D., has secured about $39 million from a Turkish investment group to support the next 10 years of his group’s research on new antibodies for obesity and other metabolic diseases.
– NextCure has ramped up its antibody-drug conjugate pivot, penning a $745 million deal for the ex-China rights to Simcere Zaiming’s phase 1-stage tumor asset.
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.
